Stephen Basil Thomas - 27 Jun 2024 Form 3 Insider Report for Eliem Therapeutics, Inc. (CLYM)

Reporting relationship
Director
Issuer ticker
CLYM
Reported as of
27 Jun 2024
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
27 Jun 2024, 19:01:24 UTC
Next SEC filing
03 Jan 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Emily Pimblett, Attorney-in-Fact

Key filing fact

Stephen Basil Thomas filed Form 3 for Eliem Therapeutics, Inc. (CLYM) on 27 Jun 2024.

Key facts

  • This page summarizes Stephen Basil Thomas's Form 3 filing for Eliem Therapeutics, Inc. (CLYM).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 27 Jun 2024, 19:01.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Additional SEC filing notes

Filing notes and footnotes

Ownership status

The filing reports no beneficially owned securities.

SEC remarks

Exhibit Index: 24.1 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .